Your browser doesn't support javascript.
loading
Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-institutional Japan-wide database.
Chikamatsu, Sotaro; Shiota, Masaki; Onozawa, Mizuki; Hinotsu, Shiro; Kitagawa, Yasuhide; Sakamoto, Shinichi; Kawai, Taketo; Eto, Masatoshi; Kume, Haruki; Akaza, Hideyuki.
Affiliation
  • Chikamatsu S; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Shiota M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Onozawa M; Department of Urology, International University of Health and Welfare, Narita Hospital, Chiba, Japan.
  • Hinotsu S; Department of Biostatistics and Clinical Epidemiology, Sapporo Medical University, Sapporo, Japan.
  • Kitagawa Y; Department of Urology, Komatsu Municipal Hospital, Komatsu, Japan.
  • Sakamoto S; Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Kawai T; Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Eto M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Kume H; Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Akaza H; Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Int J Urol ; 28(9): 927-935, 2021 Sep.
Article in En | MEDLINE | ID: mdl-34028097
OBJECTIVES: The objectives of this study were to analyze the conditional survival and prognostic factors in androgen deprivation therapy for prostate cancer using the Japan Study Group of Prostate Cancer database. METHODS: Data on patients treated with primary androgen deprivation therapy between 2001 and 2003 from a nationwide database of the Japan Study Group of Prostate Cancer were used. The conditional 5-year progression-free rate, cancer-specific survival and overall survival, as well as the conditional mortality owing to prostate cancer and other causes were calculated as per subgroups. Prognostic factors for progression-free rate, cancer-specific survival and overall survival at each time after androgen deprivation therapy initiation were calculated using the Cox proportional hazards model. RESULTS: The conditional 5-year progression-free rate and cancer-specific survival, but not overall survival, gradually increased with time. The prognostic impact of stage IV characteristics (T4, N1 and M1) changed over time; however, the prognostic impact of the Gleason score remained unchanged. In the subgroup analysis, prostate-specific mortality risk reduced over time in patients with stage IV prostate cancer, whereas non-prostate cancer mortality increased over time in elderly patients. CONCLUSIONS: Information regarding conditional survival and mortality obtained in this study would provide a benchmark for physicians and cancer survivors.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Androgen Antagonists Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Humans / Male Country/Region as subject: Asia Language: En Journal: Int J Urol Journal subject: UROLOGIA Year: 2021 Type: Article Affiliation country: Japan

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Androgen Antagonists Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Humans / Male Country/Region as subject: Asia Language: En Journal: Int J Urol Journal subject: UROLOGIA Year: 2021 Type: Article Affiliation country: Japan